MicroPort CardioFlow’s Next-Gen Defibrillator Wins Fast-Track Review in China

MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) just unveiled an update.

MicroPort CardioFlow Medtech announced that its new-generation implantable cardioverter defibrillator TILEN/EYLEN has been accepted into China’s special review pathway for innovative medical devices. The device is expected to become the first domestically developed MRI-conditional ICD with proprietary intellectual property rights, underscoring the group’s push to close key technology gaps in high-end cardiac care.

As a core project under a national R&D program, TILEN/EYLEN offers auto-MRI functionality, remote follow-up via Bluetooth-based systems and domestic data centers, and extended device longevity to reduce replacement risks and costs. Following NMPA approval of its PLATINIUM series in 2024 as the first locally produced ICD, the fast-track review for TILEN/EYLEN is poised to accelerate domestic MRI-conditional ICD production and strengthen the company’s competitive position in China’s cardiac rhythm management sector, though commercialization is not yet assured.

The most recent analyst rating on (HK:2160) stock is a Sell with a HK$0.74 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.

More about MicroPort CardioFlow Medtech Corp.

MicroPort CardioFlow Medtech Corp. is a China-focused cardiovascular medical device company specializing in cardiac rhythm management technologies. Its portfolio includes implantable cardioverter defibrillators designed to prevent sudden cardiac death, with a strategic emphasis on developing innovative, domestically produced high-energy defibrillation solutions for the Chinese market.

Average Trading Volume: 6,844,499

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.97B

Find detailed analytics on 2160 stock on TipRanks’ Stock Analysis page.